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F I R S T  G E N E R A T I O N  D R U G - E L U T I N G  S T E N T S
In in-stent restenosis, drug-eluting stents (DES) are superior compared with bare 
metal stents (BMS). However, there are concerns about safety because of the reports 
of increased risk of late and very late stent thrombosis. Stent thrombosis remains a 
major pitfall in contemporary percutaneous coronary intervention (PCI), leading to 
high rates of death and nonfatal myocardial infarction.1,2 After the US approval of 
the first two DES, the sirolimus-eluting stent (Cypher) in 2003 and paclitaxel-elut-
ing stent (Taxus) in 2004, concern was raised about the safety of the devices due to 
the occurrence of late and very late stent thrombosis. Pooled analyses of available 
randomized trails at the time, however, showed similar rates of death and myocardial 
infarction in patients treated with one of these DES compared to the BMS counter-
part in randomized clinical trials.3 Registry studies also supported the safety of DES 
in unselected patients and off-label type lesions and identified predictors of stent 
thrombosis (Fig. 1).4,5 Nonetheless, knowledge of delayed healing in DES and con-
cern for stent thrombosis led to the recommendation to increase the duration of dual 
anti-platelet therapy with aspirin and clopidogrel in patients treated with a DES to 
12 months.6.The sirolimus-eluting (SES) and paclitaxel-eluting (PES) DES are often 
referred to as the first-generation DES.
S E C O N D  G E N E R A T I O N  D E S  &  C L I N I C A L  S T U D I E S
More recently, two additional DES were approved in the US, the everolimus-
eluting stent (EES) (Xience V) in 2007 and the zotarolimus-eluting stent (ZES) 
(Endeavor) in 2008. These two newer DES have similar basic components with the 
initially approved DES, with a stent platform, polymer and anti-restenotic drug. Due 
to advances in stent platforms, delivery systems and polymer biocompatibility coupled 
with the later time of approval, they are referred to as second-generation DES. These 
DES are designed from a cobalt–chromium alloy and are thinner and more flexible 
than the first-generation DES.
The antirestenotic efficacy of DES technology is based on the local delivery and 
modulated release of cytotoxic drugs targeted at inhibition of neointimal hyperplasia. 
Control of drug-release kinetics is a critical component of device efficacy. To date 
this has been most effectively performed by stent coatings comprised of non-erodable 
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(permanent) polymer which facilitate drug loading and delay 
elution of the active drug. In fact all 4 systems currently ap-
proved by the Food and Drug Administration (FDA) use a 
permanent polymer-based drug release system. Balancing the 
need for lipophilicity (to bind active drug) with hydrophilicity 
(which offers superior biocompatibility) is a key challenge in 
polymer technology. Delayed arterial healing (DAH) following 
DES implantation has been demonstrated in human autopsy 
studies and animal models and is implicated in late throm-
botic occlusion and delayed loss of antirestenotic efficacy. It 
is characterized by 1) persistent fibrin deposition; 2) delayed 
endothelialization; 3) chronic inflammation; and 4) persistent 
platelet activation. Within segment heterogeneity in degree of 
healing is typical. Inflammatory response to polymer residue 
plays an important role and may be non-specific (monocyte-
macrophage predominant) or hypersensitivity related. 7 Failure 
of early preclinical models to sufficiently predict DAH in man 
was an important problem. Second-generation DES attempt 
to address the issue of DAH by using thinner stent struts, 
lower drug load and more biocompatible polymer. However, 
substantive comparative data among DES are lacking.
The SPIRIT program evaluated Xience V compared to 
Taxus in a series of studies. In patients with simple lesions and 
low-risk profiles, the Xience V resulted in reduced late loss at 
6 to 8 months and non-inferior rates of 9-month target vessel 
failure compared to the Taxus (Fig. 2).8-11 The findings of the 
COMPARE trial suggest an even greater benefit of Xience 
V compared to Taxus when used in unselected patients with 
potentially more complex lesion types than examined in the 
SPIRIT trials. However, longer follow-up is needed to deter-
mine if the initial benefits seen with Xience V will persist.
In terms of safety, the SPIRIT studies were not powered 
to detect differences in rare events such as stent thrombosis, 
but mortality was similar and myocardial infarction rates 
similar or lower in Xience compared to Taxus.8-10 Although 
the rates of stent thrombosis were numerically lower in the 
Xience V patients, the relative safety compared to Taxus in 
patients on or off dual anti-platelet therapy is not certain. The 
low rates of late and very late stent thrombosis with Xience 
are encouraging. Pre-clinical studies of stent healing suggest 
that endothelialization, a surrogate for stent thrombosis risk, 
is more rapid with Xience than the other 3 DES but that by 
28 days strut coverage is similar.
The Xience V Stent Evaluated at Rotterdam Cardiac 
Hospital (X-SEARCH) registry is a single-center registry of 
649 consecutive patients treated with EES. Patients treated 
with the Xience stent were compared with patients who were 
treated in the past with BMS, SES (RESEARCH registry) and 
PES (T-SEARCH registry). In this registry, patients treated 
with Xience were older; more often had myocardial infarc-
tion, and had more complicated lesions compared to the other 
groups. At 6 months, after adjustment, Xience was superior 
to BMS for target vessel revascularization and major adverse 
cardiac events (MACE), and had similar clinical outcomes to 
SES. Similar to the SPIRIT trials, PES had a higher risk of 
MACE compared to EES, extending the findings to a high 
risk, all-comers population.12
N E W E R  R A N D O M I Z E D  C L I N I C A L 
S T U D I E S
Very recently, the following studies with extended fol-
low-up from randomized clinical trials for the first “second-
generation” DES have been published for the first time and 
should be “reassuring” in terms of clinical benefit and safety 
of these devices:
Four-year results from ENDEAVOR II, demonstrating the 
superiority of the Endeavor zotarolimus-eluting stent over 
the bare-metal Driver stent in reducing repeat target vessel 
revascularization (TVR), with no significant differences 
-
FIGURE 1. Incidence of stent thrombosis in patients with se-
lected characteristics.5
FIGURE 2. Incidence of stent thrombosis in SPIRIT III trial.11
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in quality-adjusted survival or cost.13
Three-year results from the SPIRIT II study of the Xience 
V everolimus-eluting stent vs the Taxus stent, demonstrat-
ing lower rates of cardiac death, myocardial infarction, 
target lesion revascularization (TLR), stent thrombosis, 
and major adverse cardiac events (MACE) in the Xience-
treated patients.14
Three-year results from the ENDEAVOR III trial, com-
paring the Endeavor DES with the Cypher sirolimus-elut-
ing stent, suggesting that the newer stent is associated with 
a reduced rate of death or myocardial infarction, although 
also with higher use of bypass grafting (CABG). Costs are 
similar for the use of both stents.15
Two-year results from the ENDEAVOR IV trial com-
paring the Endeavor with the Taxus. The results showed 
similar overall TVR, but fewer myocardial infarctions in 
the Endeavor group, with similar TLR and no differences 
in costs or cost-effectiveness.16
In addition, the “extended-use” of these stents (i.e., in 
those with more complex lesions/disease than the kinds of 
patients enrolled in the pivotal trials) does not seem to be ac-
companied with higher rates of complications. This has been 
shown by the very recent publication of an Italian registry 
which suggested that the devices were used predominantly 
for off-label use (almost 72% of stents) and associated with 
a relatively low rate of MACE (10.6%) and TLR (7.9%) and 
the E-Five registry of the Endeavor stent. In the latter study, 
researchers reported 12-month results, with relatively low rates 
of MACE, cardiac death, myocardial infarction, and TLR, 
despite the fact that 74.4% were «high-risk».17,18
C O N C L U S I O N  A N D  F U T U R E 
P E R S P E C T I V E
Each DES differs in stent platform, drug, and polymer, 
which may result in differences in stent performance in terms 
of efficacy in preventing intimal hyperplasia and safety from 
stent thrombosis due to delayed healing. In addition to advan-
tages in deliverability, the second-generation DES may have 
superior long-term safety with similar or greater clinical ef-
ficacy compared to first-generation DES. More head-to-head 
randomized controlled trials are needed, however, before 
conclusions can be made. At present the focus of development 
of DES is towards biodegradable polymer coatings which offer 
the attractive prospect of controlled drug-release without the 
potential for late polymer-associated adverse effects. Whether 
their promise for greater safety holds true, it remains to be 
seen in the upcoming and ongoing studies.
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